Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview

Bibliography

• Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs 2007;16:1002-7
   PubMedGoogle Scholar
• Gupta R, Walunj SS, Tokala RK, Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 Diabetes. Curr Drug Targets 2009;10:71-87
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Irwin N, Flatt PR, Patterson S, Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert- butylaminoquinoxaline. Eur J Pharmacol 2010;628:268-73
   PubMed Web of Science ®Google Scholar
• Nagakura T, Yasuda N, Yamazaki K, Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001;284:501-6
   PubMed Web of Science ®Google Scholar
• Heins J, Welker P, Schonlein C, Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim Biophys Acta 1988;954:161-9
   PubMed Web of Science ®Google Scholar
• Engel M, Hoffmann T, Wagner L, The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003;100:5063-8
   PubMed Web of Science ®Google Scholar
• Aertgeerts K, Ye S, Tennant MG, Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004;13:412-21
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
   PubMed Web of Science ®Google Scholar
• Blow DM, Birktoft JJ, Hartley BS. Role of a buried acid group in the mechanism of action of Chymotrypsin. Nature 1969;221:337-40
   PubMed Web of Science ®Google Scholar
• Wang XM, Yao TW, Nadvi NA, Fibroblast activation protein and chronic liver disease. Front Biosci 2008;13:3168-80
   PubMed Web of Science ®Google Scholar
• Keane Y, B-type natriuretic peptide FM, Nadvi NA, Neuropeptide YY are novel substrates of fibroblast activation P and peptide substance protein-alpha. FEBS J 2011: published online 9 March 2011, doi: 10.1111/j.1742-4658.2011.08051.x
   Google Scholar
• Ajami K, Pitman MR, Wilson CH, Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 2008;582:819-25
   PubMed Web of Science ®Google Scholar
• Geiss-Friedlander R, Parmentier N, Moller U, The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 2009;284:27211-19
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
   PubMed Web of Science ®Google Scholar
• Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009;17:1783-802
   PubMed Web of Science ®Google Scholar
• Mulakayala N, Reddy UC, Iqbal J, Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview. Tetrahedron 2010;66:4919-38
   Web of Science ®Google Scholar
• Kanstrup AB, Sams CK, Lundbeck JM, DPP-IV-inhibiting purine derivatives for the treatment of diabetes. WO2003004496; 2003
   Google Scholar
• Himmelsbach F, Mark M, Eckhardt M, Xanthine derivative, production and use thereof as a medicament. WO2002068420; 2002
   Google Scholar
• Feng J, Zhang Z, Wallace MB, Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wallace MB, Feng J, Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem 2011;54:510-24
   PubMed Web of Science ®Google Scholar
• Kodimuthali A, Prasunamba PL, Pal M. Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring. Beilstein J Org Chem 2010: published online 1 July 2010, doi: 10.3762/bjoc.6.71
   Google Scholar
• Liu H, Ko SB, Josien H, Selective N-functionalization of 6-substituted-2-pyridones. Tetrahedron Lett 1995;36:8917-20
   Web of Science ®Google Scholar
• Feng J, Gwaltney SL, Stafford JA, Process for the preparation of pyrimidinedione derivatives. WO2007035629; 2007
   Google Scholar
• Marom E, Mizhiritskii M, Rubnov S. Process for the preparation of alogliptin. WO 2010109468 A1; 2010
   Google Scholar
• Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008;9:402-13
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffmann PK, Hassiepen U, Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-61
   PubMed Web of Science ®Google Scholar
• Christopher R, Davenport M, Gwaltney S, Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys. Diabetes 2006;55: Abs 452-P
   Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008;588:325-32
   PubMed Web of Science ®Google Scholar
• Nagakura T, Yasuda N, Yamazaki K, Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 2003;52:81-6
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 2009;157:415-26
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12:224-33
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009;329:669-76
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51
   PubMed Web of Science ®Google Scholar
• Mu J, Petrov A, Eiermann GJ, Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009;623:148-54
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP, Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704
   PubMed Web of Science ®Google Scholar
• Matveyenko AV, Dry S, Cox HI, Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-15
   PubMed Web of Science ®Google Scholar
• Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008;57:1331-9
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Voelker F, Merriam K, The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011;650:703-7
   PubMed Web of Science ®Google Scholar
• Karim A, Bridson W, Fleck P, Disposition of the dipeptidyl peptidase-4 inhibitor [14C]alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects. Abs Ann Meet Exposition Am Aassoc Pharm Scientists 2007
   Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol 2009;602:448-54
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L, Single dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [poster 538 P]. Diabetes 2008;57:A160
   Web of Science ®Google Scholar
• Karim A, Fleck P, Dorsey D, Single dose pharmacokinetics of alogliptin benzoate (SYR-322) in subjects with moderate hepatic impairment [abstract 107]. J Clin Pharmacol 2007;47:1207
   Web of Science ®Google Scholar
• Launches of “NESINA®” for treatment of type 2 Diabetes, “UNISIA®” for treatment of hypertension and “Vectibix®”, anti-cancer agent, in Japan. Takeda Pharmaceuticals Press release 2010
   Google Scholar
• Takeda submits application in Japan for additional indications of alogliptin for combination therapy with sulfonylurea and combination therapy with biguanide. Takeda Pharmaceuticals Press release 2010
   Google Scholar
• Takeda receives FDA complete response letter for alogliptin, an investigational treatment for type 2 Diabetes. Takeda Pharmaceuticals Press release 2009
   Google Scholar
• Takeda initiates cardiovascular outcomes trial for alogliptin, an investigational treatment for type 2 Diabetes. Takeda Pharmaceuticals Press release 2009 (ClinicalTrials.gov Identifier: NCT00968708)
   Google Scholar
• Japan set for wave of new drug launches. Available from: http://www.pharmatimes.com/article/10-06-08/Japan_set_for_wave_of_new_drug_launches.aspx
   Google Scholar
• Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007;24:223-32
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8
   PubMed Web of Science ®Google Scholar
• Karasik A, Aschner P, Katzeff H, Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96
   PubMed Web of Science ®Google Scholar
• Stein PP, Williams-Herman D, Khatami H, Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with type 2 diabetes: Pooled analysis of 5141 patients in clinical trials for up to 2 years. Diabetes 2007;56(Suppl 1): Abs 0534-P
   Google Scholar
• Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metab Syndr Obesity Targets Ther 2009;2:117-26
   PubMedGoogle Scholar
• Patient information Januvia. 2007. Available from: www.fda.gov/medwatch/safety/2007/Oct_PI/Januvia_PI.pdf. [Last Accessed 22 October 2010]
   Google Scholar
• He H, Tran P, Yin H, Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009;37:536-44
   PubMed Web of Science ®Google Scholar
• New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies. Novartis AG Press release 2007
   Google Scholar
• FDA prescribing information Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm [Last accessed on 22 October 2010]
   Google Scholar
• Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671-90
   PubMedGoogle Scholar